Unlocking the metabolic secrets of cancer: Our “Metabolism and Cancer” team studies how cellular metabolism drives cancer growth, drug resistance, and metastasis. We use cutting-edge laboratory experiments, computational tools and clinical trials to validate our discoveries in cancer patients.
MAIN RESEARCH LINES
Metabolic inhibitors for cancer therapy
Mitochondria, senescence, and cancer
Metabolo-immunotherapy
Group members
IP
Established researcher (Miguel Servet)
Postdoctoral researcher (INVESTIGO)
Predoctoral researcher
Predoctoral researcher
Predoctoral researcher
Established researcher (Unit of Clinical Research, ICO-Girona)
Established researcher (Hospital Trueta)
Publications
Cancer Treat Rev. 2017 Jul;58:61-69. doi: 10.1016/j.ctrv.2017.06.003. Epub 2017 Jun 23. ABSTRACT Signal transducer and activator of transcription 3 (STAT3) has a prominent role in mediating resistance to conventional chemo-/radio-therapies and modern targeted drugs. While a number of STAT3 inhibitors have been shown to enhance the efficacy of therapeutic agents in vitro, the majority of […]
Oncol Rep. 2017 Jul;38(1):263-270. doi: 10.3892/or.2017.5682. Epub 2017 May 30. ABSTRACT Patients with wild-type KRAS metastatic colorectal cancer (mCRC) that harbors NRAS activating mutations do not benefit from anti-EGFR therapies. Very little is known about oncogenic NRAS signaling driving mCRC unresponsiveness to the EGFR-directed antibody cetuximab. Using a system of paired NRAS-mutant and wild-type isogenic […]
Front Cell Dev Biol. 2017 May 5;5:49. doi: 10.3389/fcell.2017.00049. eCollection 2017. ABSTRACT The inability of adult tissues to transitorily generate cells with functional stem cell-like properties is a major obstacle to tissue self-repair. Nuclear reprogramming-like phenomena that induce a transient acquisition of epigenetic plasticity and phenotype malleability may constitute a reparative route through which human […]
Oncotarget. 2017 May 23;8(21):35019-35032. doi: 10.18632/oncotarget.16558. ABSTRACT Denosumab, a monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), might be a novel preventative therapy for BRCA1-mutation carriers at high risk of developing breast cancer. Beyond its well-recognized bone-targeted activity impeding osteoclastogenesis, denosumab has been proposed to interfere with the cross-talk between RANKL-producing sensor […]
Cell Cycle. 2017 Jun 3;16(11):1022-1028. doi: 10.1080/15384101.2017.1310353. Epub 2017 Apr 7. ABSTRACT The increased propensity of BRCA1 mutation carriers to develop aggressive breast tumors with stem-like properties begins to be understood in terms of osteoprotegerin (OPG)-unrestricted cross-talk between RANKL-overproducing progesterone-sensor cells and cancer-initiating RANK+ responder cells that reside within pre-malignant BRCA1mut/+ breast epithelial tissue. We […]
Collaborations
Ruth Lupu | Mayo Clinic, Rochester, USA
Pilar Blancafort | Harry Perkins Institute of Medical Research, Perth, Australia
Francesca Cutruzzolà | Sapienza University, Rome, Italy
Tomás Alarcón | ICREA-Centre de Recerca Matemàtica (CRM), Reus, Spain
Sílvia Osuna | ICREA-Institut de Química Computacional i Catàlisi (IQCC), Girona, Spain
Josep Sardanyés | Centre de Recerca Matemàtica (CRM), Barcelona, Spain
José Antonio Encinar | Universidad Miguel Hernández, Elche, Spain
Vicente Micol | Universidad Miguel Hernández, Elche, Spain
Antonio Segura-Carretero | Universidad de Granada, Granada, Spain
Jorge Joven | Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
Carlos Peña Garay | Laboratorio Subterráneo de Canfranc (LSC), Spain
Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952
Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069
Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087
Sureda’s & Farre’s Lab